NCT02513381View on ClinicalTrials.gov

Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Polycystic Ovary Syndrome
Interventions
OTHER

Vitamin D3, 3200IU

Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.

OTHER

Placebo

Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.

Trial Locations (1)

HU3 2RW

Michael White Centre for Diabetes and Endocrinology, Hull

All Listed Sponsors
collaborator

University of Hull

OTHER

lead

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

NCT02513381 - Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter